Request Processed
Your registration request has been processed. We will contact you soon.
Register
First name
Last name
Email
Company
Toggle navigation
Toggle navigation
Login
Register
About
Contact Us
1
2
3
4
5
6
Next ›
Last »
ICER Says Lecanemab Has Insufficient Net Health Benefit, “Low” Long-Term Value At Current Pricing; Post-Approval Evidence Will Be Key, But How?
March 20, 2023
“Conditional Approval” Redux? FDA Gives Advisory Committee “Two Scenarios” For Biogen/Ionis’ Tofersen In ALS: Accelerated Approval Or Full Approval
March 20, 2023
Prevision Policy Clips | CDER Office Of Compliance Annual Report
March 20, 2023
Biomarker Studies Proposed For Use In Labeling Require Subject-Level Data Submission, FDA Says In Revised PKG Guidance; “Voluntary” Program Ending
March 17, 2023
Opioid Overdose Treatments In Spotlight At FDA Workshop; Agency Hopes To Spread Message That Abstinence Is Not The Only Acceptable Endpoint
March 17, 2023
Paxlovid Endorsed For EUA-To-NDA Approval On Strength Of FDA Reassurances On Efficacy; DDIs Are Main Safety Concern
March 17, 2023
Prevision Policy Clips | Sarepta DMD Gene Therapy Will Go To Advisory Committee Ahead Of May 29 User Fee Deadline
March 17, 2023
CMS Casts Broad Net For Price Negotiation Targets: All NDAs With Same “Active Ingredient” Will Be Covered By “A Single Price”; Tight Timeline For Biosimilar Sponsors To Seek Delays
March 16, 2023
CMS Price Negotiation Benchmarks: Reference Pricing Tied To Therapeutic Alternatives Where Available, FSS Pricing Where Not; “Starting Point” Is Likely Key To Final Price
March 16, 2023
Prevision Policy Clips | CBER Gene Therapy “Super Office”: Witten’s Interim Director Role Likely To Run At Least Into Summer
March 16, 2023
Part B Inflation Rebate List Released By CMS: No Major Products Affected, First Year Collections May Not Reach $20 Million
March 15, 2023
Prevision Policy Clips | FDA Draft Guidance On Long-Acting Local Anesthetics Encourages Data Collection On Opioid Use
March 15, 2023
Pfizer Paxlovid NDA Conversion Complicated By Lack Of Efficacy In Vaccinated Populations; Approval Still Likely Heading To Panel Review
March 14, 2023
GAO Report Spotlights FDA Advanced Manufacturing Initiatives, Urges Agency To Flesh Out Metrics For ETP and FRAME
March 14, 2023
Prevision Policy Clips | Veterans Affairs Department To Cover Eisai/Biogen’s Leqembi For Alzheimer’s But Restricts Use To 65 And Older
March 14, 2023
Get Ready To DANCE: FDA/Duke RWE Negative Controls Meeting Features Two Projects, But Agency Says Activities Are Only At “The Start”
March 13, 2023
Prevision Policy Clips | GAO Advanced Manufacturing Report Spotlights FDA Efforts
March 13, 2023
FDA Proposes Emerging Pathogens Preparedness Program As PAHPA Add-On In Budget “Wish List”; LDTs Not Included In Requests To Congress
March 10, 2023
“Infected Trials,” Remote Inspection Guidances Among 18 CBER/CDER COVID Policies That Will Be Retained Post-Emergency; FDA Outlines Wind-Down Plan For Others
March 10, 2023
Genentech Polivy Wins Strong Support For First-Line DLBCL Claim Despite Skeptical FDA Review; ODAC Losing Streak Over
March 10, 2023
Prevision Policy Clips | FDA’s Gastrointestinal Drugs Advisory Committee To Review Intercept’s Ocaliva For NASH On May 19
March 10, 2023
HCV Subscription Model Is $11 Bil. Silver Lining For Drug Developers In White House Budget; Price Cuts Are Much Bigger Item, But Far Less Viable
March 10, 2023
Prevision Policy Clips | House Opioid Bill Would Require Manufacturers And Distributors To Report “Suspicious” Orders
March 9, 2023
Cell Therapy “Assessment Aid” Would Encourage Use Of Data Extrapolation For Next-Generation Oncology Indications; CBER Is Open To Idea
March 9, 2023
FDA Questions “Modest” Efficacy Of Genentech Polivy In First-Line DBCL Setting; Accelerated Approval Status For Refractory Disease Not At Issue For Panel Review
March 8, 2023
1
2
3
4
5
6
Next ›
Last »